Cytiva, a Danaher company and a leader in the life sciences industry, has signed a FlexFactory™ contract with Yoshindo, supporting the company’s plans to establish domestic biosimilar drug substances manufacturing capabilities for the Japanese market.
Yoshindo plans to begin supplying biosimilar products manufactured in Yoshindo’s own plant located in Toyama from 2028 onward, contributing to a more stable domestic supply of affordable biologic medicines in Japan.
The project will enable Yoshindo to manufacture biosimilar drug substances using single‑use technologies, helping accelerate facility readiness while maintaining flexibility for future needs.
Cytiva’s FlexFactory™ solution integrates standardised, modular bioprocessing technologies designed to shorten the time from facility design to GMP production without deep prior expertise in single‑use systems. Through a process design phase completed in early 2026, Yoshindo was able to visualise its manufacturing operations and forecast key operating requirements.
The facility is expected to support monoclonal antibody biosimilar drug substances manufacturing for the Japan market. This marks a significant step forward for Yoshindo’s biopharmaceutical business, for which Yoshindo has accumulated expertise over the past decade. This investment is partially supported by Japan’s Ministry of Health, Labour and Welfare (MHLW).
